Vertex releases compelling Phase II results for VX-548 in DPN

13 December 2023

Vertex Pharmaceuticals’ (Nasdaq: VRTX) shares were up 9.2% at $390.42 mid-morning, after it announced positive results from its Phase II dose-ranging study of the non-opioid selective NaV1.8 inhibitor VX-548 in people with painful diabetic peripheral neuropathy (DPN).

VX-548 is Vertex’ fourth attempt to develop a sodium channel Nav1.8 inhibitor, after VX-128, VX-150 and VX-961 failed to impress.

Treatment with all doses of VX-548 resulted in a statistically-significant and clinically-meaningful reduction in the primary endpoint of change from baseline in the weekly average of daily pain intensity on a Numeric Pain Rating Scale (NPRS) at Week 12. The study also included an active reference arm of pregabalin to support the evaluation of the VX-548 treatment effect.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK